1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

AdvaMed Chair Nadim Yared Talks Challenges, Priorities

 
• By David Filmore

The AdvaMed chairman and CVRx CEO spoke to Medtech Insight from the floor of the Pennsylvania Convention Center at this year's MedTech Conference. The discussion focused on the industry's push for a breakthrough reimbursement pathway, the impact of US-China tariff wars and the industry's answer to challenges from grassroots patient groups on device safety, among other challenges and priorities.

Philadelphia, Pa. USA, Aug. 11, 2018: main entrance of the Pennsylvania Convention Center with police during the Philly Free Streets event.
The MedTech Conference was held this week at the Pennsylvania Convention Center in Philadelphia

AdvaMed is hopeful the Trump administration will propose a new reimbursement pathway by year's end that could supply temporary, automatic coverage to US FDA-designated breakthrough devices on the condition of data collection. That is among the issues discussed by AdvaMed Chairman and CVRx Inc. President and CEO Nadim Yared in a interview with Medtech Insight's editor David Filmore at the 2018 MedTech Conference in Philadelphia. Check out the interview in the video below.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

UK Healthtech Center Of Excellence Given Key MHRA Digital Regulation Role

 
• By Ashley Yeo

Ahead of the 11 June UK spending review and its anticipated funding uplift for healthcare and life sciences, the MHRA announced an expansion of its digital expertise by creating a dedicated hub in Leeds, a renowned center of medtech excellence.

Where Do Questions Surrounding The EU’s AI Act Leave The Medtech Industry?

 
• By Amanda Maxwell

The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.

Medtech Giants Brace for Tariffs Impact: Responses Range From Financial To Philosophical

 
• By Marion Webb, Shubham Singh, and Nancy Pham

Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.

Final Curtain For LDTs? FDA Will Not Appeal District Court Decision To Vacate Final Rule

 
• By Brian Bossetta

The US FDA has given up on its effort to regulate lab-developed tests as medical devices, at least for now. The agency will not appeal a decision from the Eastern District of Texas that tossed out the FDA’s final rule, leaving the agency with few cards.

More from Policy & Regulation

‘Small Business’ Applications For Waiver Of Device User Fees To Be Streamlined By US FDA

 
• By Brian Bossetta

FDA moves forward with implementing previous draft guidance and will consolidate forms, but the agency estimates limited impact in the total reporting burden.

FDA Outlines Responsibilities For Owners Of Transferred 510(k)s

 
• By Elizabeth Orr

The US FDA's new draft guidance details the responsibilities of new owners of 510(k) clearances, including making timely updates device listings in FURLS and GUDID to maintain accurate information for safety alerts and recalls. Comments on the draft are accepted until 4 August.

US House Budget Sets FDA FY26 Funding At $3.2B

 
• By Sue Sutter and Derrick Gingery

A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.